Overview
IDA Pathology, Etiology, and the Role of Hepcidin Across At-Risk Patient Populations
Expert Insights #2 Dr. Boccia
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
Iron-deficiency anemia (IDA) is a widespread condition affecting multiple patient populations, which can range from elderly patients and women of childbearing age to cancer patients, chronic kidney disease patients, and persons with gastroenterological conditions such as IBD, among others. IDA also affects populations not traditionally screened for iron deficiency, such as those with certain cardiovascular conditions such as congestive heart failure and cardiomyopathy. In this activity, a leading hematologist will discuss the pathology of IDA in multiple clinical patient subsets, as well as how hepcidin, a peptide hormone, regulates iron in the body in both normal human physiology and in multiple disease states.
This activity is intended for gastroenterologists, hematologists, oncologists, and other healthcare professionals treating gastrointestinal and cancer related anemia.
Iron deficiency anemia is associated with myriad disease-related causes in the United States, making it a widespread problem leading to significant morbidity and occasional mortality. Further, it is often easily treatable via either oral or IV iron therapy. Although IDA is a manageable disease with appropriate treatment, widespread undertreatment/underdiagnoses of this disease is apparent across patient demographics. Clinicians require up-to-date knowledge of anemia assessment, diagnosis and management of IDA to reduce its burden and improve clinical outcomes.
Upon completion of this activity, participants will be able to:
• Define IDA etiology, signs/symptoms, and epidemiology across patient subsets.
• Outline established and novel treatment options for IDA, including efficacy, routes of administration, and clinical appropriateness for IDA across multiple patient subsets and clinical severity levels.
• Analyze clinical examples of IDA and develop feasible treatment solutions based on relevant symptom severity, practice setting, and patient subset.
Sponsored by Academy for Continued Healthcare Learning
Supported by an educational grant from American Regent
Ralph V. Boccia, MD
Chief Medical Officer
Medical Director, Center for Cancer and Blood Disorders
Clinical Associate Professor of Medicine
Georgetown University
Washington, DC
Chief Medical Officer
Medical Director, Center for Cancer and Blood Disorders
Clinical Associate Professor of Medicine
Georgetown University
Washington, DC
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity.
Ralph V. Boccia, MD
Speakers' Bureau: Daiichi-Sankyo
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: This activity discusses common off-label uses of IV iron formulations for treatment of iron-deficiency anemia across multiple patient subsets, not all of which are currently FDA-indicated to receive IV iron. Practitioners are advised to use appropriate caution, and consult the FDA black-box safety warnings on several currently available IV iron products and formulations.
Ralph V. Boccia, MD
Speakers' Bureau: Daiichi-Sankyo
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: This activity discusses common off-label uses of IV iron formulations for treatment of iron-deficiency anemia across multiple patient subsets, not all of which are currently FDA-indicated to receive IV iron. Practitioners are advised to use appropriate caution, and consult the FDA black-box safety warnings on several currently available IV iron products and formulations.
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pre-test, view the online webinar and complete the post-test and evaluation forms. To receive credit, 60% must be achieved on the post-test. A certificate will be immediately available. There is no fee for the generation of the certificate.
Inquiries may be directed to ACHL at (877) 444-8435, ext. 228.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
